ArticleAntimicrobial agents and chemotherapy2008
Adsorption of amikacin, a significant mechanism of elimination by hemofiltration.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Extracorporeal Blood Purification with the oXiris® Filter for Patients with Sepsis and Hyperinflammatory Conditions: The Asia-Pacific oXiris Expert Meeting 2024 Consensus Statements.Blood purification · 2025Guideline
- Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study.Annals of intensive care · 2025Article
- Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy.BMC nephrology · 2024Article
- Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model.Journal of pharmaceutical health care and sciences · 2023Article
- UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy.Journal of clinical laboratory analysis · 2023Article
- Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.Clinical pharmacokinetics · 2022Article
- Adsorption of vancomycin, gentamycin, ciprofloxacin and tygecycline on the filters in continuous renal replacement therapy circuits: in full blood in vitro study.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2021Article
- Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy.BMC nephrology · 2021Article
- High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?Annals of intensive care · 2020Article
- Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: in vitro studies.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2020Article
- Reply to Baud and Houzé, "ShouldAntimicrobial agents and chemotherapy · 2020Article
- ShouldAntimicrobial agents and chemotherapy · 2020Article
- No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure.Critical care (London, England) · 2020Article
- In vitro Evaluation of Linezolid and Doripenem Clearance with Different Hemofilters.Blood purification · 2020Article
- Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation.Critical care (London, England) · 2018Observational
- [Dose adjustment of anti-infective drugs in patients with renal failure and renal replacement therapy in intensive care medicine : Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2018Review
- Article
- [Antibiotic dosing for renal function disorders and continuous renal replacement therapy].Der Anaesthesist · 2015Review
- Treatment with echinocandins during continuous renal replacement therapy.Critical care (London, England) · 2014Review
- Amikacin pharmacokinetics during continuous veno-venous hemodialysis.Infectious diseases and therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We used an in vitro model of continuous venovenous hemofiltration (CVVH) to characterize amikacin adsorption by polyacrylonitrile (PAN) and polyamide filters. A blood-crystalloid mixture dosed with amikacin was pumped from a reservoir through a hemofiltration circuit and back to the reservoir. All ultrafiltrate was also returned to the reservoir. The level of adsorption was calculated from the fall in the amikacin concentration. The dose and the initial concentration of amikacin were varied, as were the pH, the type of hemofilter, and the hemofilter surface area. The reversibility of adsorption and the effect of repeated dosing were also studied. The level of adsorption by 0.6-m2 PAN filters was significantly greater than that by 0.6-m2 polyamide filters. Adsorption was increased by increasing the dose of amikacin even when the initial concentration was unchanged. It was unaffected by the pH (pH 6.8 or 7.4) or the hemofilter surface area (0.6 m2 or 0.9 m2). Repeated doses of amikacin resulted in further adsorption. In a saturation experiment, the maximum adsorptive capacity of 0.6-m2 PAN hemofilters was at least 546.9 mg (range, 427.6 to 577.5 mg). The adsorption of amikacin by hemofilters is irreversible and was associated with the dose and the hemofilter material but not the hemofilter surface area. Close monitoring of peak amikacin levels should be considered for patients receiving CVVH with PAN hemofilters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.